Semaglutide reduces cardiovascular risk across risk subgroups
GLP-1 agonist semaglutide significantly decreases risk of cardiovascular events and death across different risk groups of patients with type 2 diabetes, secondary analysis of clinical trial data has found.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Heart